Intestinal Failure-Associated Liver Disease

IFALD (intestinal failure-associated liver disease) is liver disease occurring in the context of intestinal failure (IF) requiring long-term parenteral nutrition (PN), in the absence of another primary hepatic etiology. It is not a single pathologic entity but a spectrum of liver injury driven by the combination of the underlying intestinal disease, PN composition, and absence of enteral stimulation.

Four drivers of IFALD converge on cholestasis/steatosis, progressing to fibrosis over time

Context: Chronic IF and Home PN

IFALD occurs principally in patients with chronic (Type III) IF — those dependent on home PN for months to years. For full IF classification, SBS etiology, PN complications, and intestinal rehabilitation, see Intestinal Failure & Transplantation →

Prognostic Threshold — Rising Bilirubin

Total bilirubin >3–5 mg/dL on serial measurements while on PN indicates significant IFALD. A rising bilirubin trend despite PN optimization is the most important clinical marker of progression and represents a clear indication to initiate discussion about intestinal and liver transplant evaluation. Refer early — do not wait for decompensation.

Quick recall

1/2

What is the biochemical pattern of liver injury in IFALD, and why?

Tap to reveal →

Feature	Neonates / Infants	Adults
Predominant pattern	Cholestasis → rapid progression to cirrhosis	Hepatic steatosis, then cholestasis with PN duration
Onset	Weeks	Months to years
Progression	Can be fulminant; major cause of morbidity/mortality in pediatric SBS	More indolent; fibrosis over years
Histology	Bile duct proliferation, portal fibrosis, cholestasis	Steatosis, steatohepatitis, pericellular fibrosis

Risk Factor	Mechanism
Long duration of PN	Cumulative hepatotoxicity from lipid emulsions and glucose excess
Lack of enteral nutrition	Loss of enterohepatic bile acid circulation; GLP-2/CCK deficiency; bacterial overgrowth; mucosal atrophy
Soy-based lipid emulsions (Intralipid)	High omega-6 phytosterols competitively inhibit bile acid synthesis; suppress FXR; pro-inflammatory
Recurrent CRBSIs	Each septic episode accelerates hepatic inflammation and fibrosis; Gram-positive organisms common
Small bowel bacterial overgrowth (SBBO)	Endotoxemia and LPS translocation → activates hepatic TLR4 → increases hepatic inflammation
Overfeeding (excess dextrose)	De novo hepatic lipogenesis → steatosis → steatohepatitis
Prematurity (neonates)	Immature bile acid transport; reduced hepatic conjugation capacity
Absence of gallbladder emptying	Biliary sludge and cholelithiasis from CCK deficiency → worsens cholestasis

Management of IFALD is multimodal. No single intervention is sufficient; the six strategies below are applied concurrently and titrated to the clinical trajectory of the individual patient.

Strategy 1

Maximize Enteral Nutrition

Even trophic feeding reduces IFALD by stimulating CCK → gallbladder contraction → bile flow
Maintains mucosal integrity and villous height; reduces SBBO via luminal acid and motility stimulation
Promotes GLP-2 release (intestinotrophic — stimulates bowel adaptation in SBS)
Target: even 10–20 mL/hour of enteral tube feeds or oral intake in patients with residual gut function

Strategy 2

Fish Oil-Based Lipid Emulsions

Switch from soybean oil (Intralipid) to SMOFlipid is the current standard of care for established IFALD
Omega-3 fatty acids: anti-inflammatory, displace phytosterols, restore FXR signaling, reduce hepatic steatosis
Target total lipid dose: ≤1 g/kg/day; consider cycling off lipids 1–2 days per week
Omegaven (100% fish oil): FDA-approved since July 2018 for paediatric patients with PN-associated cholestasis; strong evidence for reversal of established IFALD in neonates

Strategy 3

Cyclic PN

Infuse PN over 10–14 hours overnight rather than continuous 24-hour infusion
Allows a rest period with normal fasting physiology — insulin levels fall, hepatic fat oxidation resumes
Reduces hepatic steatosis and cholestasis; improves quality of life
Contraindicated if patient cannot tolerate the higher hourly infusion rate or has fluid overload

Strategy 4

Ursodeoxycholic Acid (UDCA)

Commonly used adjunctively for cholestasis in IFALD; displaces toxic hydrophobic bile acids and promotes bile flow
Dose: 10–15 mg/kg/day orally or via enteral tube
Most evidence in pediatric IFALD; adult data inconclusive but low risk
Reasonable to use given established benefit in other cholestatic diseases (PBC, PSC)

Strategy 5

Avoid Overfeeding

Excess dextrose drives de novo hepatic lipogenesis → steatosis → steatohepatitis
Target non-protein calories: 20–25 kcal/kg/day in stable adults (reduce in obesity)
Carbohydrate:fat ratio — aim for 60:40 to 50:50; avoid excessive glucose predominance
Monitor serum glucose during PN; hyperglycemia worsens outcomes independently

Strategy 6

Catheter Care & CRBSI Prevention

Ethanol lock therapy (70%, ≥2 hours dwell): significantly reduces CRBSI rates; endorsed by ASPEN
Strict aseptic technique during catheter access; dedicated PN line — avoid blood draws through PN line
CVC venous access preservation is critical — each lost access site can impact future transplant candidacy
Each CRBSI episode is associated with a measurable surge in bilirubin and accelerated hepatic fibrosis

Lipid Emulsion Comparison

Emulsion	Status	Composition	IFALD Impact
Soybean oil (Intralipid 20%)	Standard	~55% omega-6 linoleic acid; high phytosterol content	Associated with IFALD progression — avoid as sole lipid source in established IFALD
SMOFlipid (Fresenius Kabi)	FDA approved for adults 2016; paediatric indication added subsequently	Soybean oil 30% + MCT 30% + olive oil 25% + fish oil 15%; lower phytosterols than soy-only	Reduces IFALD progression; current standard of care for established IFALD.
Omegaven (Fresenius Kabi)	FDA approved July 2018 (paediatric PN-associated cholestasis)	100% fish oil (EPA + DHA)	Evidence for reversal of established IFALD in neonates; commercially available in the US since Nov 2018 — no longer compassionate-use only

Teduglutide and Indirect IFALD Benefit

By promoting bowel adaptation and reducing PN dependence, teduglutide may indirectly reduce IFALD burden — less PN means less cumulative lipid and glucose hepatotoxicity. Full prescribing detail, trial data (STEPS trial, Gastroenterology 2012), and monitoring requirements are covered on the Intestinal Failure & Transplantation page →

Quick recall

1/2

Why does switching from Intralipid to SMOFlipid reduce IFALD, and what is the target lipid dose?

Tap to reveal →

IFALD Indicator	Clinical Threshold / Significance
Rising serum bilirubin	Total bilirubin >3–5 mg/dL (predominantly direct/conjugated) on serial measurements while on PN; rising trend despite lipid switch and PN optimization is the most important marker
Histologic fibrosis progression	Bridging fibrosis (F3) or cirrhosis (F4) on liver biopsy; portal hypertension on imaging
IFALD-related decompensation	Ascites, variceal hemorrhage, or hepatic encephalopathy from IFALD cirrhosis → urgent combined liver-intestinal transplant evaluation

Intestinal Failure-Associated Liver Disease

Lipid Emulsion Comparison

References